DOVER (OCT. 15, 2021) – The Delaware Division of Public Health (DPH) is providing an update on the most recent statistics related to coronavirus disease 2019 (COVID-19) in Delaware, as of 6 p.m. Thursday, Oct. 14, 2021.

Total positive cases since March 11, 2020: 139,380
7-day average of new positive cases: 391.6, a decrease from 445.7 last week
7-day average for the percentage of total positive tests: 8.2%, an increase from 7.8% last week
Hospitalizations: 207, a decrease of 27 from last week; Critically ill: 30, a decrease of two from last week
Total COVID-19 deaths: 2,021
Total COVID-19 deaths since last week: 24, including 7 from a review of vital statistic records.

COVID-19 Vaccinations:

Total number of doses administered in Delaware: 1,216,916
Percentage of Delawareans 12+ who have received at least one dose (CDC data): 78.5%
Percentage of Delawareans 18+ who received at least one dose (CDC data): 80.2%
Delawareans who are fully vaccinated: 524,838 **

** The total number of fully vaccinated Delawareans, according to DelVAX, shows a decrease this week due to a technical error where booster doses were inadvertently added to this category. This issue has been rectified.

 

Delawareans who are fully vaccinated have significant protection from COVID-19 infection, serious illness and death. All qualifying Delawareans should get vaccinated. For the latest information on the COVID-19 vaccine in Delaware, visit de.gov/getmyvaccine. Delaware’s latest COVID-19 vaccination statistics can be found under the Vaccine Tracker dashboard at de.gov/healthycommunity.

 

COVID-19 Case Vaccination Status Report:

The following report captures a weekly breakdown of vaccination status for cases, deaths, and hospitalizations for the time frame for Oct. 4 – Oct 10. The report highlights the significant percentage of cases and hospitalized individuals in Delaware who are unvaccinated, or only partially vaccinated.

Weekly Overview (10/4 -10/10)
Unvaccinated Cases
Total Unvaccinated / Partially Vaccinated Cases	2300
Total Cases	2975
Percent of Unvaccinated / Partially Vaccinated Cases	77%
Hospitalizations
Unvaccinated / Partially Vaccinated Hospitalized  Cases	71
Total Hospitalized Cases	96
Percent of Unvaccinated / Partially Vaccinated Hospitalized  Cases	74%
Deaths
Unvaccinated / Partially Vaccinated COVID-19 Deaths	14
Total COVID-19 Deaths	19
Percent of Unvaccinated / Partially Vaccinated COVID-19 Deaths	74%

 

 

 

Breakthrough Cases (cumulative since vaccinations began):

Fully vaccinated Delawareans: 524,838
Total breakthrough cases: 4,683 or 9/10 of 1% of vaccinated individuals
Total breakthrough hospitalizations: 85
Total breakthrough deaths: 59

A breakthrough case is defined as testing positive for COVID-19 after an individual has been fully vaccinated for two weeks or more – although it does not mean that the infection occurred after vaccination.

 

COVID-19 Variant Cases in Delaware:

In the last week, 368 test samples were sequenced through routine surveillance of test specimens. Of those test samples, 246 (66.8%) sequenced at the DPH Lab were positive for a variant strain, as were eight additional specimens sequenced at an outside lab. Out of the 254 variant positive samples, all but one was identified as the Delta strain.

 

The Centers for Disease Control and Prevention (CDC) recently updated the classifications of known COVID-19 variants. Currently, the Delta variant is the only variant being monitored by the CDC as a “variant of concern” and no other variants are currently classified as “variants of interest.” For more information regarding CDC variant classifications, visit https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html.

 

DPH COVID-19 Vaccine Mobile Units:

DPH officials in partnership with medical staff from the Delaware National Guard (DNG) have launched mobile units to offer COVID-19 vaccines in underserved communities. With the official start of Flu Season, the flu vaccine will also be available and can be administered at the same time as the COVID-19 vaccine.

 

The mobile units, which utilize trailers to transport the vaccine and provide vaccinations, are scheduled to visit these communities in New Castle, Kent and Sussex counties next week. COVID-19 testing will be available at each location.

 

Tuesday, October 19

Spence’s Bazaar, 550 S. New Street, Dover, 10:00 a.m. – 12:00 p.m.

Shoppes at Hamlet, 1015 Walker Road, Dover, 1:00 p.m. – 3:00 p.m.

 

Wednesday, October 20

Wawa, 2800 N. DuPont Hwy, Dover, 10:00 a.m. – 12:00 p.m.

Edgehill Shopping Center, 43 S. Dupont Hwy, Dover, 1:00 p.m. – 3:00 p.m.

Wilmington Farmers Market, 1000 N. Market Street, Wilmington, 10:00 a.m. – 2:00 p.m.

Adams Four Shopping Center, 800 West 3rd Street, Wilmington, 3:00 p.m. – 5:00 p.m.

 

Thursday, October 21

Simmons Food/Simmons Feed Ingredients, 7494 Federalsburg Road, Bridgeville, 10:00 a.m. – 12:00 p.m. and 1:00 p.m. – 3:00 p.m.

Impact Life Job Fair, 6 North Clifton Avenue, Wilmington, 11:00 a.m. – 4:00 p.m.

 

Friday, October 22

12th and Northeast Boulevard – near Family Dollar Store, Wilmington, 11:00 a.m. – 3:00 p.m.

 

*dates may be rescheduled if there is inclement weather

 

For a full list of community-based events statewide including those organized by vaccinating partners and community groups at de.gov/getmyvaccine.

 

Long-term Care Statistics:

As of 6:00 p.m. Thursday, Oct. 14, there have been a total of 2,903 positive COVID-19 cases involving long-term care residents, and 849 residents of Delaware long-term care facilities have died from complications related to COVID-19.

 

Resources:

Individuals with general questions about COVID-19 should call Delaware 2-1-1, individuals who are deaf or hard of hearing can text their ZIP code to 898-211, or email delaware211@uwde.org. Hours of operation are:

 

Monday – Friday: 8:00 a.m. to 9:00 p.m.

Saturday: 9:00 a.m. to 5:00 p.m.

 

Medically related questions regarding testing, symptoms, and health-related guidance can be submitted by email at DPHCall@delaware.gov.

 

Delawareans 18 or older are encouraged to download COVID Alert DE, Delaware’s free exposure notification app to help protect your neighbors while ensuring your privacy. Download on the App Store or Google Play

 

DPH will continue to update the public as more information becomes available. For the latest on Delaware’s response, go to de.gov/coronavirus.

DOVER (Oct. 15, 2021) – The Delaware Division of Public Health (DPH) is strongly reminding Delawareans to use caution when around unknown wild animals, including feral cats and stray animals. The reminder comes after a skunk in Greenwood recently tested positive for rabies after attacking a stray cat. The cat escaped and was later found dead in a nearby area.

“This situation is a good reminder for everyone to not touch, feed or approach stray animals. Had that cat returned to its feral colony and been infected with rabies from the attack, it could have transmitted the infection to other cats,” said DPH Medical Director Dr. Rick Hong. “For the safety of everyone, the best thing to do to avoid risk of exposure to rabies, is to stay away from unfamiliar wild or stray animals.”

Rabies is a preventable disease. DPH recommends that individuals take the following steps to prevent rabies exposure:

• All dogs, cats, and ferrets 6 months of age and older are required by Delaware law to be vaccinated against rabies by a licensed veterinarian.
• Pet owners can reduce the possibility of pets being exposed to rabies by keeping them indoors and not letting them roam free. It is especially important for pet owners who do allow their cats to roam outdoors to vaccinate their pets.
• Do not touch or otherwise handle wild or unfamiliar animals, including cats and dogs, even if they appear friendly.
• Do not keep your pet’s food or water outdoors; bowls can attract wild and stray animals.
• Do not feed feral animals, including cats, as the risk of rabies in wildlife is significant.
• Spaying or neutering your pet may reduce the tendency to roam or fight and, thus, reduce the chance they will be exposed to rabies.
• Keep your garbage securely covered.
• Consider vaccinating livestock and horses, as well. It is recommended to consult with your private veterinarian if you have any questions regarding whether your animal(s) should be vaccinated against rabies.

Since Jan. 1, 2021, DPH has performed rabies tests on 171 animals, 17 of which were confirmed to be rabid, which includes one dog, two raccoons, two skunks (including this one), one fox, three cats, six bats, one cow and a deer. DPH only announces those rabies cases for which it is possible the animal had unknown contacts with additional humans or pets.

In 2020, DPH performed rabies tests on 121 animals, four of which were confirmed to be rabid, including one raccoon, one bat, and two cats. Two additional Delaware animals were tested out of state and confirmed positive, bringing the state total to six.

Rabies is an infectious disease affecting the nervous system of humans and other mammals. Infection can occur through the bite or scratch of an infected animal or if saliva from such an animal gets into the eyes, nose, mouth, or an opening in the skin. Rabies in humans and animals cannot be cured once symptoms appear. Therefore, if a human has been exposed, and the animal is unavailable to be quarantined or tested, DPH recommends that people receive post-exposure prophylaxis (PEP) treatment, a series of four vaccinations, as a precautionary measure.

If You Encounter an Animal Behaving Aggressively:

• If you encounter a wild animal other than a feral cat or possibly dog behaving aggressively, it is recommended you contact the Delaware Department of Natural Resources and Environmental Control’s (DNREC) Wildlife Section at 302-739-9912 or 302-735-3600. Staff will determine whether it is more appropriate to refer callers to a private nuisance wildlife control operator. A listing of nuisance wildlife control operators can be found at https://wildlifehelp.org/. Calls after hours and on weekends can be made to the 24-hour dispatch number at 800-523-3336.
• Do not throw items at the animal or make loud banging noises, which may startle the animal and cause it to attack. Instead, your initial response – if the animal is behaving in an aggressive manner or appears to be foaming at the mouth – should be to raise your hands above your head to make yourself appear larger to the animal while slowly backing away from it. If the animal starts coming toward you, raise your voice and yell sternly at it, “Get away!” If all that fails, use any means to protect yourself including throwing an object at the animal or trying to keep it away by using a long stick, shovel, or fishing pole.
• If you encounter a stray or feral domestic animal, such as a cat or dog, behaving aggressively, contact the Office of Animal Welfare at 302-255-4646.

If You Encounter a Sick or Injured Animal:

• To report a sick or hurt wild animal, Delaware residents are asked to contact the DNREC’s Wildlife Section at 302-739-9912 or 302-735-3600. Staff will determine whether it is more appropriate to refer callers to a permitted volunteer wildlife rehabilitator.
• If you encounter a sick stray domestic animal, such as a cat or dog, contact the Office of Animal Welfare at 302-255-4646.

For more information on the DPH rabies program, visit www.dhss.delaware.gov/dhss/dph/dpc/rabies.html or call 1-866-972-9705 or 302-744-4995. For more information on rabies, visit the Centers for Disease Control and Prevention at www.cdc.gov/rabies/.

DOVER (Oct. 13, 2021) –The Delaware Division of Developmental Disabilities Services (DDDS) announced today that Easterseals of Delaware & Maryland’s Eastern Shore will become the Division’s new “Agency with Choice” Provider, providing self-directed services to individuals with intellectual and developmental disabilities and their families. Self-directed supports provide additional flexibility to individuals and families to build the service system that suits them best.

Marissa Catalon, Director of the Division of Developmental Disabilities Services said, “Self-directed care options empower people to control the supports they receive – whether those supports are needed at home, at a job, or out in the community. It’s our most flexible option, and we’re excited to have Easterseals as a new provider of this service option for our community.”

Easterseals will work with individuals receiving personal care and respite services via the DDDS Lifespan Medicaid Waiver Program and their families to provide assistance with training, enrollment, staff-hiring and onboarding.

Pam Reuther, Chief Operating Officer of Easterseals of Delaware & Maryland’s Eastern Shore, shared the enthusiasm for this new partnership. “Easterseals has a long history of working to meet the unique needs of every individual we support. We’re excited to have been selected as the new Agency with Choice Provider for DDDS and look forward to enabling more individuals with intellectual/developmental disabilities and their families to play a stronger role in building the supports they need.”

DDDS first made self-directed care through the Agency with Choice program available to its service recipients in 2017 in partnership with Consumer Direct Care Network. “We’re incredibly grateful for the work Consumer Direct Care Network did in partnership with the State to build and grow this program over the last four years,” said DDDS Director Catalon. “Because of their commitment and stewardship of this service, we feel confident in our ability to transition this program to our new partner and continue its expansion in our service system.”

DDDS is one of 10 divisions in the Department of Health and Social Services. It serves more than 5,000 service recipients statewide.

 

NEW CASTLE (Oct. 12, 2021) – The Delaware Department of Health and Social Services’ Division of Medicaid and Medical Assistance (DMMA) and Division of Developmental Disabilities Services (DDDS) are pleased to announce immediate efforts to stabilize and strengthen the home and community-based services (HCBS) workforce that serves thousands of individuals across Delaware. The State will make targeted payments to recruit and retain the Direct Support Professionals (DSPs) who are the critical infrastructure of the human services support system.

Through the American Rescue Plan Act (ARPA), Congress provided a temporary 10% increase in federal matching funds to enhance, expand, and strengthen home and community-based services supported by Medicaid.

“Investing in our Direct Support Professional workforce is the first step toward strengthening and expanding our system as a whole,” DHSS Secretary Molly Magarik said. “These investments will be used to support DSPs operating across our entire network of home and community-based services, but will be made available first to DSPs supporting Delawareans with intellectual/developmental disabilities. Maintaining the integrity of this workforce ensures continued availability of this community lifeline for the individuals and families who rely on DSPs every single day.”

Approximately 3,000 DSPs play a vital role in providing critical support for Delawareans with intellectual and developmental disabilities (IDD) living in the community. During the COVID-19 pandemic, these essential staff are enabling Delawareans with IDD to maintain their jobs and live safely in their communities.

In order to access this additional federal funding, states must develop a detailed spending plan demonstrating how and where the funds will be used. Delaware’s spending plan will include payments directly to DSPs:

• Each new DSP, employed on or after May 1, 2021, who works a minimum of 25 hours a week could receive a recruitment payment of up to $1,000.
• Existing DSPs who were employed prior to April 30, 2021, and who worked an average of 25 hours a week would be eligible for a one-time $1,000 payment.

DHSS intends to begin submitting payments to providers later this month.

Additional details on supports for DSPs working in other sectors of HCBS will be released soon. Additional information on Delaware’s ARPA spending plan can be found on the DHSS website.

-30-

 

The Department of Health and Social Services is committed to improving the quality of life of Delaware’s citizens by promoting health and well-being, fostering self-sufficiency, and protecting vulnerable populations.

 

 

DOVER, DEL. (Oct. 11, 2021) – According to the latest cancer data from the Division of Public Health (DPH), Delaware’s mortality rate for all cancer sites combined (all-site cancer) improved in most categories during the last decade; however, the state remains 15th-highest in the U.S. for the timeframe of 2013-2017, which is unchanged from 2012-2016. Delaware also remains second-highest nationally for all-site cancer incidence during the same period, which may be partly due to the state’s continued increases in early detection and screening.

DPH presented its data report, Cancer Incidence and Mortality in Delaware, 2013-2017, to the Delaware Cancer Consortium (DCC) on Monday. The annual report seeks to compare Delaware’s cancer incidence and mortality trends for 2013-2017 to those of the U.S. over the same period. DPH also summarizes how Delaware and U.S. cancer rates have changed from the five-year periods of 2003-2007 to 2013-2017. This year’s report analyzes all-site cancer and eight site-specific cancer types: breast, colorectal, lung, cervical, kidney, leukemia, oral and prostate.

DPH also issued a new compendium report, Census Tract-Level Cancer Incidence in Delaware, 2013-2017, which replaces previous secondary analysis reports. This report presents modified calculations and detailed maps with all-site cancer incidence rates by census tract.

From 2003-2007 to 2013-2017 in Delaware, all-site cancer mortality rates decreased 26% among non-Hispanic African American males and 15% among non-Hispanic Caucasian males, yet increased 18% among Hispanic males. Among Delaware females during the same period, all-site cancer mortality rates decreased 12% among non-Hispanic African Americans, 15% among non-Hispanic Caucasians, and 12% among Hispanics. DPH attributes these decreases to screening and early detection.

“After decades of dedicated early detection and screening efforts by a wide array of partners, it’s reassuring to see improvement in certain areas,” Governor John Carney said. “I commend the Delaware Cancer Consortium and the Division of Public Health for expertly coordinating our state’s cancer prevention advocacy and education. I also thank those Delawareans who get their recommended cancer screenings, and encourage everyone to do the same.”

For 2013-2017, the state’s all-site cancer mortality rate (171.0 deaths per 100,000 people) was higher than the U.S. rate (158.3 deaths per 100,000). Also, for 2013-2017:

Delaware males (204.1 per 100,000) ranked 17th for all-site cancer mortality (18th in 2012-2016) and had higher rates compared to U.S. males (189.5 per 100,000).

Delaware females (146.3.1 per 100,000) had a higher all-site cancer mortality rate compared to U.S. females (135.7 per 100,000) and ranked 17th for all-site cancer mortality, an improvement from 14th in 2012-2016.

“The data show us clearly that early screening and prevention are critical for bringing down cancer mortality rates. Unfortunately, the COVID-19 pandemic has caused many people to delay cancer screenings and other preventive chronic disease care, and economically disadvantaged communities are typically impacted the most,” said Molly Magarik, Secretary of the Delaware Department of Health and Social Services. “Free cancer screenings are available to eligible Delawareans and we know they can lead to earlier diagnosis and to saving lives.”

Regarding incidence or diagnosis of new cancer cases, in 2013-2017, there were nearly 29,000 new cancer cases diagnosed in Delaware, a slight increase from the 28,581 cases in 2012-2016 . Of those cases, 51% of those diagnosed were male, and 78% were non-Hispanic Caucasians. Delaware saw statistically higher rates (484.3 per 100,000) for all-site cancer incidence than the U.S. (435.0 per 100,000). Also, for 2013-2017:

Delaware males (531.5 per 100,000) had a higher all-site cancer incidence rate compared to U.S. males (472.9 per 100,000), ranking fourth nationally, an improvement from third in 2012-2016.
Delaware females (450.8 per 100,000) had a higher rate of all-site cancer incidence in 2013-2017 compared to U.S. females (410.5 per 100,000); their ranking improved to ninth from fifth in 2012-2016.
Noticeable improvements exist among many racial and ethnic groups, likely due to Delaware’s health equity initiatives. While there was no significant statistical difference in all-site cancer incidence rates between non-Hispanic Caucasians (496.9 per 100,00) and non-Hispanic African Americans (485.5 per 100,000) in the 2013-2017 period, Hispanics (389.1 per 100,000) had a lower all-site cancer incidence rate compared to both non-Hispanic Caucasians and non-Hispanic African Americans.

In Delaware, from 2003-2007 to 2013-2017, all-site cancer incidence rates decreased 12% among non-Hispanic Caucasian males, 22% among non-Hispanic African-American males, and12% in Hispanic males. For females during the same 10-year period, the all-site cancer incidence rate decreased 9% among Hispanic females, but increased 3% among non-Hispanic Caucasians and less than 1% among non-Hispanic African Americans.

“In order to address the disparities that persist in cancer incidence and mortality, we must address the circumstances in which people are born, grow up, live, work, and age and the systems put in place to deal with illness,” said DPH Director Dr. Karyl Rattay. “These social determinants of health include housing and neighborhood conditions, educational and economic factors, transportation systems, social connections, and other social factors. We must look at the racial disparities across the cancer continuum from prevention to end-of-life care that result from differences in the social determinants of health as no longer endurable.”

BREAST CANCER

Breast cancer is the most common type of cancer among women in Delaware. In 2013-2017:

From 2003-2007 to 2013-2017, female breast cancer mortality in Delaware decreased 2%, compared to the U.S. decline of 15%.
Female breast cancer incidence rate for Delaware (135.4 per 100,000) was higher than the U.S. female rate (126.8 per 100,000).
Delaware’s percent of female breast cancer cases diagnosed at the local stage increased from 42% in 1980-1984 to 68% in 2013-2017.
Delaware females 40 years of age and older who reported having a mammogram within the previous two years ranked third-highest nationally (79%) in the 2018 Behavioral Risk Factor Survey.
COLORECTAL CANCER

Colorectal cancer is the fourth most diagnosed cancer in the U.S. and Delaware. Delaware ranked 11th-highest in prevalence in the U.S. for meeting the U.S. Preventive Services Task Force colorectal screening recommendations. In addition:

Between 2003-2007 and 2013-2017, incidence rates for colorectal cancer decreased by 26% in Delaware and 21% in the U.S.
During the same 10-year time period, mortality rates for colorectal cancer decreased by 21% both in Delaware and in the U.S.
Nearly 73% of Delawareans age 50-74 years reported meeting the recommendations, more than the national median of 70%.
For 2013-2017 in Delaware, non-Hispanic African Americans (44.6 per 100,000) had a statistically higher colorectal cancer incidence rate compared to non-Hispanic Caucasians (37.6 per 100,000).
Non-Hispanic Caucasians accounted for 78% of colorectal cancer deaths in Delaware in 2013-2017.
LUNG CANCER

Lung cancer remains the most frequently diagnosed cancer and the most common cause of cancer deaths in the U.S. and Delaware. In addition:

Delaware males (75.7 per 100,000) had a higher lung cancer incidence rate compared to Delaware females (61.3 per 100,000).
Delaware’s 2013-2017 lung cancer incidence rate improved to 17th, compared to 10th in 2012-2016.
Delaware’s 2013-2017 lung cancer mortality rank improved to 16th from 14th in 2012-2016.
Non-Hispanic Caucasians accounted for 82% of lung cancer cases in 2013-2017.
Hispanics (29.1 per 100,000) had a lower lung cancer incidence rate compared to both non-Hispanic Caucasians (70.7 per 100,000) and non-Hispanic African Americans (65.5 per 100,000).
Over the past decade, cancer incidence rates decreased among all sex, race, and ethnic groups. From 2003-2007 to 2013-2017 in Delaware, lung cancer incidence rates decreased:

· 21% in non-Hispanic Caucasian males

· 11% in non-Hispanic Caucasian females

· 31% in non-Hispanic African-American males

· 13% in non-Hispanic African-American females

· 45% in Hispanic males

· 55% in Hispanic females

 

PROSTATE CANCER

Prostate cancer is the most diagnosed cancer among males in the U.S. and Delaware. According to the 2020 Behavioral Risk Factor Survey (BRFS), 33% of Delaware males 40 and older reported having a Prostate Specific Antigen (PSA) test in the past two years, compared to the national median prevalence of 32%. In addition:

Between 2003-2007 and 2013-2017, prostate cancer incidence rates decreased by 30% in Delaware and 33% in the U.S.
Between 2003-2007 and 2013-2017, mortality rates for prostate cancer decreased by 31% in Delaware and 24% in the U.S.
In 2013-2017, Delaware’s non-Hispanic African Americans (205.8 per 100,000) had a much higher prostate cancer incidence rate compared to non-Hispanic Caucasians (110.3 per 100,000) and Hispanics (114.3 per 100,000).
Non-Hispanic African Americans (34.1 per 100,000) in Delaware had a higher prostate cancer mortality rate in 2013-2017 compared to Delaware’s non-Hispanic Caucasians (14.2 per 100,000).

CERVICAL CANCER

Cervical cancer accounted for 1% of all female cancer cases in Delaware in 2013-2017. According to the BRFS, 83% of Delaware women 21-65 years of age reported that they had had a Pap test within the previous three years, compared to the national median of 80% among U.S. women of the same ages. In addition:

Delaware ranked 20th in the U.S. for cervical cancer incidence, a six-place improvement from 14th in 2012-2016.
Non-Hispanic Caucasians accounted for 70% of Delaware’s cervical cancer cases in 2013-2017.
Non-Hispanic Caucasian females (48%) had a higher proportion of cervical cancer diagnosed at the local stage compared to non-Hispanic African American females (35%).
In 2013-2017, Delaware’s cervical cancer mortality rate (2.6 per 100,000) was not statistically significantly different from the U.S. cervical cancer mortality rate (2.3 per 100,000).

RESOURCES

 

In addition to cancer data, the Cancer Incidence and Mortality in Delaware, 2013-2017 report also includes information about risk factors, screening, state of diagnosis, data trends, and cancer survivorship. The Census Tract-Level Cancer Incidence in Delaware, 2013-2017 compendium report presents analyses of all-site cancer incidence rates by census tract.

For more information about DPH’s cancer prevention and treatment work, visit https://www.dhss.delaware.gov/dhss/dph/dpc/cancer.html or call the Delaware Comprehensive Cancer Control Program at 302-744-1020. For more information about the DCC, visit https://www.healthydelaware.org/Consortium. To learn how to prevent, detect, and treat chronic diseases and obtain assistance with a cancer screening, visit the Healthy Delaware website at HealthyDelaware.org.

The Screening for Life (SFL) program provides payment for cancer screening tests to qualified Delaware adults. Eligible individuals can receive office visits, mammograms and clinical breast exams, Pap tests and screening tests for prostate, colorectal, and lung cancer when recommended by a doctor. SFL also provides lung cancer screenings for eligible men and women. Contact SFL at https://www.dhss.delaware.gov/dph/dpc/sfl.html or call 302-401-4212 to speak with a screening nurse navigator.

Delaware residents 18 and older who want help quitting smoking should contact the Delaware Quitline at 1-866-409-1858 or QuitSupport.com.

For population health, environmental and social determinant of health data at the smallest geographical area available, visit the My Healthy Community data portal at de.gov/healthycommunity.